Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16782312 | 1.00 | KMT2A (0.52) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL2227135 | 1.00 | KMT2A (0.52) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL10603115 | 1.00 | KMT2A (0.52) | KMT2AMAPTCES2CES1HAO1 | |
| Fluoride SCHEMBL2400392 | 0.98 | KMT2A (0.50) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL3724208 | 0.91 | CES1 (0.44) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL25262434 | 0.89 | FAAH (0.61) | KMT2AMAPTPPARGPPARDPPARA | |
| SCHEMBL23304151 | 0.86 | KMT2A (0.50) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL5412601 | 0.85 | KDM4E (0.64) | KMT2APPARGPPARDPPARATSHR | |
| SCHEMBL1271373 | 0.82 | — | — | |
| SCHEMBL13279440 | 0.81 | KMT2A (0.50) | KMT2AMAPTHAO1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025120480-A1 | METHODS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDER | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-12 | — | — | WO | claimed |
| WO-2025022362-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSKINESIA | Clearmind Medicine Inc. (IL) | 2025-01-30 | — | — | WO | claimed |
| CN-119300814-A | Use of 5-methoxy-2-aminoindan (\"MEAI\") in a method for treating cocaine addiction | 克力迈医药公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118179438-A | Organic amine modified HMS molecular sieve and application thereof in carbon dioxide capturing | 西北大学 | 2024-06-14 | — | — | CN | claimed |
| EP-3297622-B1 | COMBINATIONS OF OXYCODONE AND N-ACYLETHANOLAMINE PALMITOYLETHANOLAMINE FOR REDUCING OPIOID-ASSOCIATED SIDE EFFECTS | SCISPARC LTD (IL) | 2023-11-01 | — | — | EP | claimed |
| CN-116568802-A | In vitro method for preparing mature red blood cells | 西湖生物医药科技(上海)有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116547207-A | Antibacterial and antiviral molded body and master batch | 三井化学东赛璐株式会社 | 2023-08-04 | — | — | CN | claimed |
| CN-114126600-A | Liposome preparation of vilanterol tritoate | 广州谷森制药有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2021243093-A1 | METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FORM VIRAL INFECTIONS | IMMUNOFLEX THERAPEUTICS INC. (CA) | 2021-12-02 | — | — | WO | claimed |
| US-20210369661-A1 | METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FROM VIRAL INFECTIONS | IMMUNOFLEX THERAPEUTICS INC. (CA) | 2021-12-02 | — | — | US | claimed |
| WO-2016185468-A1 | COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2016-11-24 | — | — | WO | claimed |
| WO-2016174661-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2016-11-03 | — | — | WO | claimed |
| EP-2460014-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES Life Sciences AG (AT) | 2012-06-06 | — | — | EP | claimed |
| WO-2011161186-A1 | METHOD FOR IN VITRO DIAGNOSING SEPSIS UTILIZING BIOMARKER COMPOSED OF MORE THAN TWO DIFFERENT TYPES OF ENDOGENOUS BIOMOLECULES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-12-29 | — | — | WO | claimed |
| EP-2284540-A1 | Method of diagnosing organ failure | BIOCRATES Life Sciences AG (AT) | 2011-02-16 | — | — | EP | claimed |
| WO-2011012553-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES LIFE SCIENCES AG (AT) | 2011-02-03 | — | — | WO | claimed |
| EP-1917007-A2 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | Rheoscience A/S (DK) | 2008-05-07 | — | — | EP | claimed |
| EP-1595146-B1 | SCREENING ASSAYS FOR CANNABINOID-LIGAND-TYPE MODULATORS OF GPR55 | ASTRAZENECA AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007006319-A2 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | RHEOSCIENCE A/S (DK) | 2007-01-18 | — | — | WO | claimed |
| WO-2001028588-A1 | CANNABINOIDS AS VASODILATORS AND CARDIOPROTECTORS AGAINST ISCHEMIA | UNIVERSITE DE MONTREAL (CA) | 2001-04-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369661-A1 | METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FROM VIRAL INFECTIONS | IFNG, CD4, MAVS | KMT2A 2000/4885MAPT 2040/4885CES2 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.